Know Cancer

or
forgot password

Phase II Study of Irinotecan and Gemcitabine (IrinoGem) Combined With 3-D Conformal Radiation Therapy for Locally Advanced Pancreatic Cancer


Phase 2/Phase 3
18 Years
N/A
Not Enrolling
Both
Pancreatic Cancer

Thank you

Trial Information

Phase II Study of Irinotecan and Gemcitabine (IrinoGem) Combined With 3-D Conformal Radiation Therapy for Locally Advanced Pancreatic Cancer


Inclusion Criteria:



- locally advanced pancreatic cancer

- performance status 0-2

- normal blood count and chemistry

- no previous chemotherapy or radiotherapy

Exclusion Criteria:

- serious concurrent systemic disease

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

time to treatment failure

Principal Investigator

Ron Epelbaum, MD

Investigator Role:

Principal Investigator

Authority:

Israel: Israeli Health Ministry Pharmaceutical Administration

Study ID:

RonIrinoGem.CTIL

NCT ID:

NCT00192712

Start Date:

November 2002

Completion Date:

September 2010

Related Keywords:

  • Pancreatic Cancer
  • carcinoma
  • pancreas
  • chemotherapy
  • radiotherapy
  • Pancreatic Neoplasms

Name

Location